Patricia Fulco

Summary

Affiliation: Virginia Commonwealth University
Country: USA

Publications

  1. ncbi Acid suppressive therapy and the effects on protease inhibitors
    Patricia Pecora Fulco
    Division of Infectious Diseases, Virginia Commonwealth University Medical Center, 401 N 12th St, PO Box 980042, Richmond, VA 23298 0042, USA
    Ann Pharmacother 40:1974-83. 2006
  2. ncbi Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent
    Patricia Fulco
    Virginia Commonwealth University, Department of Internal Medicine, Richmond, VA, USA
    Expert Rev Anti Infect Ther 4:939-45. 2006
  3. ncbi Raltegravir-based HAART regimen in a patient with large B-cell lymphoma
    Patricia Pecora Fulco
    Clinical Pharmacy Specialist in Internal Medicine HIV Clinical Associate Professor of Pharmacy, Virginia Commonwealth University Health System, Richmond, VA, USA
    Ann Pharmacother 44:377-82. 2010
  4. ncbi Acute onset of pancreatitis with concomitant use of tenofovir and didanosine
    Margaret A Kirian
    Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH, USA
    Ann Pharmacother 38:1660-3. 2004
  5. ncbi Possible antiretroviral therapy-warfarin drug interaction
    Patricia Pecora Fulco
    Department of Pharmacy, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    Pharmacotherapy 28:945-9. 2008

Collaborators

Detail Information

Publications5

  1. ncbi Acid suppressive therapy and the effects on protease inhibitors
    Patricia Pecora Fulco
    Division of Infectious Diseases, Virginia Commonwealth University Medical Center, 401 N 12th St, PO Box 980042, Richmond, VA 23298 0042, USA
    Ann Pharmacother 40:1974-83. 2006
    ..To review the literature associated with the pharmacokinetic interaction between protease inhibitors (PIs) and acid suppressive therapies and to characterize the impact of this interaction on virologic and immunologic outcomes...
  2. ncbi Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent
    Patricia Fulco
    Virginia Commonwealth University, Department of Internal Medicine, Richmond, VA, USA
    Expert Rev Anti Infect Ther 4:939-45. 2006
    ..difficile colitis. The clinical value and place in therapy of ramoplanin is dependent upon the results of Phase III trials addressing its utility in suppressing carriage of target organisms in the gastrointestinal tract or in the nares...
  3. ncbi Raltegravir-based HAART regimen in a patient with large B-cell lymphoma
    Patricia Pecora Fulco
    Clinical Pharmacy Specialist in Internal Medicine HIV Clinical Associate Professor of Pharmacy, Virginia Commonwealth University Health System, Richmond, VA, USA
    Ann Pharmacother 44:377-82. 2010
    ....
  4. ncbi Acute onset of pancreatitis with concomitant use of tenofovir and didanosine
    Margaret A Kirian
    Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH, USA
    Ann Pharmacother 38:1660-3. 2004
    ..Practitioners should be aware that a significant drug interaction with resulting pancreatitis may occur even when a reduced dosage is prescribed...
  5. ncbi Possible antiretroviral therapy-warfarin drug interaction
    Patricia Pecora Fulco
    Department of Pharmacy, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    Pharmacotherapy 28:945-9. 2008
    ..Thus, practitioners should prudently monitor INRs in patients receiving warfarin with concomitant HAART that includes either a protease inhibitor or an NNRTI...